

## Xeomin® (incobotulinumtoxinA) – Expanded indication

- On May 14, 2019, Merz Pharmaceuticals announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of blepharospasm in adult patients.
  - Xeomin was previously approved for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox<sup>®</sup>).
- Xeomin is also approved for the treatment of chronic sialorrhea, upper limb spasticity, cervical dystonia, and glabellar lines.
- Blepharospasm causes muscles around the eyes to contract involuntarily. Patients suffering from blepharospasm can experience symptoms including excessive blinking, light sensitivity, dry eyes, eye irritation, and watering eyes.
  - Blepharospasm affects up to 50,000 patients in the U.S.
- The efficacy of Xeomin for the treatment of blepharospasm in treatment-naïve patients was evaluated in a double-blind study in a total of 61 patients. During the placebo-controlled phase, a fixed total dose of 25 units Xeomin, 50 units Xeomin, or placebo was administered intramuscularly at 6 injection sites per eye. The primary efficacy variable was the change from baseline in Jankovic Rating Scale (JRS) severity subscore determined at week 6 after the injection.
  - The 50 unit treatment group demonstrated statistically significant improvements in the primary endpoint vs. placebo, with a difference of -1.2 (p = 0.0004). The change from baseline in the JRS severity subscore for the 25 unit treatment group was not statistically significant, with a difference of -0.5 (p = 0.1452) vs. placebo.
- Xeomin carries a boxed warning for distant spread of toxin effect.
- In treatment-naïve patients, the recommended initial dose of Xeomin for treatment of blepharospasm is 50 units (25 units per eye). In patients previously treated with a botulinum toxin A, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the Xeomin dose.
  - The total dose of Xeomin should not exceed 100 units per treatment session (50 units per eye).
  - Xeomin is injected into the lateral and medial orbicularis oculi muscle of the upper lid; lateral canthus and the lateral orbicularis oculi muscle of the lower lid; and the corrugator muscle, if necessary. The number and location of injections may be changed in response to adverse reactions or based on the patient's response to treatment.
  - The frequency of Xeomin repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks.
  - Refer to the Xeomin drug label for dosing for all its other indications.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.